PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620
NCT05456503
Recruiting
The investigators will compare PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched cognitively normal subjects.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Perelman Center for Advance Medicine, Philadelphia, Pennsylvania
Conditions: Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
Register for Updates
Impact of Intensive Treatment of SBP on Brain Perfusion, Amyloid, and Tau (IPAT Study)
NCT05331144
Recruiting
The purpose of this study is to determine if intensive lowering of systolic blood pressure (SBP), using FDA approved medications (antihypertensive), reduces Alzheimer's Disease pathology (i.e., excessive brain amyloid and tau protein deposition) in older adults at high risk for memory decline or dementia.
Gender:
ALL
Ages:
Between 60 years and 85 years
Trial Updated:
07/31/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Dementia
Register for Updates
US Post-Market Surveillance Study of the Surfacer System
NCT05050799
Recruiting
Single arm, observational, multi-center, consecutively enrolling, post-market surveillance study. Treating patients in need of central venous access who have upper body venous occlusions or other conditions that preclude central venous access by conventional methods, and who meet the requirements described in the device labeling.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Pima Heart and Vascular, Tucson, Arizona +5 locations
Conditions: Venous Disease
Register for Updates
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT05519085
Recruiting
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: Cancer and Blood Specialty Clinic, Los Alamitos, California +265 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Register for Updates
Precision Medicine Randomized Clinical Trial Comparing Molecular Tumor Board Assisted Care to Usual Care
NCT05254795
Recruiting
This trial will compare Molecular Tumor Board (MTB) assisted care to usual care for patients who have newly diagnosed histologically or cytologically confirmed stage IIb-IV Non-Small Cell Lung Cancer (NSCLC) and are planning to undergo treatment for their cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Multi-System Analysis of Opioid Receptor Binding
NCT05528848
Recruiting
This study will enroll up to 60 adults (including 30 females and 30 males) in three cohorts of up to 20 subjects each. In all three groups, \[11C\]carfentanil whole-body PET imaging will be used to examine the central nervous system (CNS) and broader systemic opioid binding in an initial scan session. In the two groups not receiving standard of care medication assisted treatment (MAT) for opioid use disorder (OUD) the effects on \[11C\]carfentanil binding potential of the blockade of opioid bind... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/31/2025
Locations: University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
Conditions: Healthy, Opioid Use Disorder
Register for Updates
Left Ventricular Physiological Effects of Veno-Arterial Extracorporeal Membrane Oxygenation Support During Cardiogenic Shock
NCT05426083
Recruiting
A Clinical Events Committee (CEC) will include Cardiac Surgery Professor and chief of cardiac surgery Rose Kelly MD, Professor of Medicine Ganesh Raveendran MD at the University of Minnesota who is the direction of Interventional Cardiology and Professor of Medicine at the University of Minnesota David Benditt. They will review and adjudicate serious and unexpected adverse events independently from the PI and co investigators.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Acute Coronary Syndrome, Cardiogenic Shock
Register for Updates
SV2A in Older Adults
NCT05465538
Recruiting
The aim of the study is to examine the effect of cannabis use on brain synaptic density among older adults using \[11C\]UCB-J PET imaging.
Gender:
ALL
Ages:
50 years and above
Trial Updated:
07/31/2025
Locations: Conneticut Mental Health Center, New Haven, Connecticut
Conditions: Cannabis Use
Register for Updates
Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
NCT05389215
Recruiting
This is a randomized, double-blinded, placebo-controlled multicenter study to evaluate the safety and efficacy of DWN12088 in patients with Idiopathic Pulmonary Fibrosis.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/31/2025
Locations: Pulmonary Associates, PA, Mesa, Arizona +29 locations
Conditions: Idiopathic Pulmonary Fibrosis
Register for Updates
Evaluation of Patients With Gastrointestinal Disease
NCT05041374
Recruiting
Background: Ongoing and future research projects that study gastrointestinal diseases depend on access to biological samples and clinical data. Researchers want to study people who are seen and treated for these diseases. This may help them assess and treat these diseases better in the future. Objective: To collect data and samples from people being seen and/or treated for gastrointestinal problems at NIH, to use in future research. Eligibility: Adults aged 18 and older who have known or su... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/31/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lower GI Disease, Gastrointestinal Diseases
Register for Updates
A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease
NCT05531656
Recruiting
This is a multicenter randomized, double-blind, placebo-controlled Phase 2 study designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 85 years
Trial Updated:
07/31/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +45 locations
Conditions: Early Alzheimer's Disease
Register for Updates
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
NCT05533775
Recruiting
The purpose of this study is to evaluate the safety and efficacy of glofitamab, as monotherapy and in combination with a standard chemoimmunotherapy regimen: rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) in pediatric and young adult participants with relapsed and refractory (R/R) mature B-cell non-Hodgkin lymphoma (B-NHL).
Gender:
ALL
Ages:
Between 6 months and 30 years
Trial Updated:
07/31/2025
Locations: Children's Hospital of Alabama, Birmingham, Alabama +23 locations
Conditions: Mature B-Cell Non-Hodgkin Lymphoma
Register for Updates